Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | TACR2 | P21452 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TST | Q16762 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690338 | 0.85 | TMEM97 (0.61) | ESR1ADRA2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL449737 | 0.82 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL9166790 | 0.79 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL7784766 | 0.79 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL9165397 | 0.79 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL5684044 | 0.79 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL8398450 | 0.79 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL2777921 | 0.79 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL4631265 | 0.79 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL253453 | 0.79 | ESR1 (0.77) | ESR1ADRA2AADORA3TACR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-8846688-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8198286-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1485360-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7868010-B2 | N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible | PARION SCIENCES, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20090227530-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-7410968-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080176863-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-7368451-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7332496-B2 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | PARION SCIENCES, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070265280-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7247636-B2 | Phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247637-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7241766-B2 | Methods of using phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7192959-B2 | Antihistamines; antiinflammatory agents; bronchodilator agents; inflammatory bowel disorders; psoriasis | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192960-B2 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192958-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7189719-B2 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; long half-life on mucosal surfaces; pyrazinoylguanidine derivatives | PARION SCIENCES, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | ESR1 4537/4885ADRA2A 215/4885ADORA3 754/4885 |
| US-20080176863-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | ESR1 4878/4885ADRA2A 299/4885ADORA3 1890/4885 |
| US-20070265280-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | SCN1B, KCNN3, SCN2B | ESR1 4416/4885ADRA2A 170/4885ADORA3 434/4885 |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | ESR1 4537/4885ADRA2A 215/4885ADORA3 754/4885 |
| US-20090227530-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | ESR1 4537/4885ADRA2A 215/4885ADORA3 754/4885 |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | SCN1B, KCNN3, SCN2B | ESR1 4416/4885ADRA2A 170/4885ADORA3 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.